Skip to main content
Journal cover image

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

Publication ,  Journal Article
Crews, KR; Gaedigk, A; Dunnenberger, HM; Leeder, JS; Klein, TE; Caudle, KE; Haidar, CE; Shen, DD; Callaghan, JT; Sadhasivam, S; Prows, CA ...
Published in: Clin Pharmacol Ther
April 2014

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Pharmacol Ther

DOI

EISSN

1532-6535

Publication Date

April 2014

Volume

95

Issue

4

Start / End Page

376 / 382

Location

United States

Related Subject Headings

  • Polymorphism, Genetic
  • Pharmacology & Pharmacy
  • Pharmacogenetics
  • Morphine
  • Humans
  • Genotype
  • Genetic Testing
  • Cytochrome P-450 CYP2D6
  • Codeine
  • Analgesics, Opioid
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Klein, T. E., Caudle, K. E., … Clinical Pharmacogenetics Implementation Consortium, . (2014). Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther, 95(4), 376–382. https://doi.org/10.1038/clpt.2013.254
Crews, K. R., A. Gaedigk, H. M. Dunnenberger, J. S. Leeder, T. E. Klein, K. E. Caudle, C. E. Haidar, et al. “Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.Clin Pharmacol Ther 95, no. 4 (April 2014): 376–82. https://doi.org/10.1038/clpt.2013.254.
Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014 Apr;95(4):376–82.
Crews, K. R., et al. “Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.Clin Pharmacol Ther, vol. 95, no. 4, Apr. 2014, pp. 376–82. Pubmed, doi:10.1038/clpt.2013.254.
Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC, Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014 Apr;95(4):376–382.
Journal cover image

Published In

Clin Pharmacol Ther

DOI

EISSN

1532-6535

Publication Date

April 2014

Volume

95

Issue

4

Start / End Page

376 / 382

Location

United States

Related Subject Headings

  • Polymorphism, Genetic
  • Pharmacology & Pharmacy
  • Pharmacogenetics
  • Morphine
  • Humans
  • Genotype
  • Genetic Testing
  • Cytochrome P-450 CYP2D6
  • Codeine
  • Analgesics, Opioid